



# COLORADO

Department of Health Care  
Policy & Financing

## Drug Utilization Review Board MEETING AGENDA

August 13, 2024

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at  
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

### Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Brian Jackson, MD, MA (Chair)	Jeffrey Taylor, PharmD (HCPF)
Liza Claus, PharmD (Vice Chair)	Veronia Garcia, PharmD (HCPF)
Todd Brubaker, DO	Rachele Poissant, PharmD (HCPF)
Shilpa Klocke, PharmD	Julia Rawlings, PharmD (CO-DUR)
Patricia Lanius, BSP Pharm, MHA	Robert L Page II, PharmD, MSPH (CO-DUR)
Kenneth MacIntyre, DO	Gina Moore, PharmD, MBA (CO-DUR)
Ingrid Pan, PharmD	Heather Anderson, PhD (CO-DUR)
Marshal Ash, DO	Garth Wright, MPH (CO-DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the May 7, 2024 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

#### Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at [jeffrey.taylor@state.co.us](mailto:jeffrey.taylor@state.co.us)
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting

#### 7. Clinical Updates and General Orders

- FDA New Product Update
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

## 8. New Business (open for public testimony and DUR Board review)

### A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Antipsychotics, Injectable
- Androgenic Agents - Topical, Injectable, Oral
- Bone Resorption Suppression and Related Agents
- Non-Insulin Diabetes Management Classes - DPP-4is, GLP-1 Analogues, SGLT-2is
- Growth Hormones
- Phosphate Binders

#### Mass review drug classes\*

- Androgenic Agents - Topical, Injectable, Oral
- Contraceptives - Topical
- Diabetes Management Classes
  - Insulins - Rapid, Short, Intermediate, Long-Acting, Mixtures, Concentrated
  - Non-Insulins - Amylin, Biguanides, Meglitinides, Thiazolidinediones, Combinations
- Estrogen Agents - Oral/Transdermal, Injectable
- Glucagon, Self-Administered
- Prenatal Vitamins/Minerals
- Antihyperuricemics
- Benign Prostatic Hyperplasia (BPH) Agents
- Overactive Bladder Agents

*\*Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

### B. Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDL> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial review of newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization)

- OTC Choline
- Winrevair (sotatercept-csrk)
- Libervant (diazepam)
- Eohilia (budesonide)
- Adzyna (apadamtase alfa)
- Alvaiz (eltrombopag)
- Voydeya (danicipan)
- Tryvio (aprocitentan)

## 9. Adjournment

*Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.*

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)

